Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET
Company Participants
Hiromitsu Ikeda – Chief Communications and IR OfficerNaoki Okamura – Representative Director, President & Chief Executive OfficerClaus Zieler – Chief Commercial Officer & Medical Affairs OfficerTadaaki Taniguchi – Chief Medical OfficerAtsushi Kitamura – Chief Financial Officer
Conference Call Participants
Hidemaru Yamaguchi – Citigroup SecuritiesSeiji Wakao – JPMorgan SecuritiesAkinori Ueda – Goldman Sachs SecuritiesShinichiro Muraoka – Morgan Stanley MUFG SecuritiesHiroyuki Matsubara – Nomura SecuritiesMiki Sogi – Sanford C. BernsteinKazuaki Hashiguchi – Daiwa SecuritiesFumiyoshi Sakai – UBS Securities
Hiromitsu Ikeda
Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today. I’m delighted to serve as a moderator. I’m Ikeda, Chief Communications and IR Officer. Thank you for your time.
Today after presentation, we move on to Q&A session. Presentation will be made based on the material posted on our website under the IR Meeting Section. We have simultaneous translation between Japanese and English including Q&A. We cannot guarantee the accuracy of the translation. Thank you for understanding. You can choose the language from the menu on the Zoom webinar screen. If you select the original language, you can listen to the original sound without going through the translation.
Disclaimer for today, this material or representation by representatives for the company, and their answers and statement in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. They contain information on pharmaceuticals, including compounds under development, but this information is not intended to make any representations or advertisements
